Completed PHASE2 INTERVENTIONAL 2-arm NCT00699803

Study of T-PRED(TM) Compared to Pred Forte(R)

Sponsor: Bausch & Lomb Incorporated

Conditions Cataract

Updated 9 times since 2017 Last updated: Sep 2, 2020 Started: May 31, 2008 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00699803, this PHASE2 trial focuses on Cataract and remains completed. Sponsored by Bausch & Lomb Incorporated, it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Oct 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Oct 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch & Lomb Incorporated

Data source: Bausch & Lomb Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Irvine, United States